Shobha Parvathala, MD
Internal Medicine · Tempe, AZNPI 1851385868
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,491, 2.0 times the $743 reported in 2019. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$667
- Novo Nordisk$609
- AbbVie$559
- Boehringer Ingelheim$411
- Lilly USA, LLC$404
- GSK$383
- plus $3K from 44 others
What the payments were for
- Food & beverage$6,393100%
- Education$130%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$143
- AIRSUPRA$138
- BREZTRI$138
- FARXIGA$122
- SOLIQUA 100/33$122
How this compares
$6,421 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 68 | $102,250 |
| OzempicSemaglutide | 79 | $90,497 |
| JardianceEmpagliflozin | 70 | $89,245 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 40 | $49,049 |
| MounjaroTirzepatide | 30 | $43,661 |
| ProliaDenosumab | 18 | $30,265 |
| EliquisApixaban | 16 | $27,864 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $22,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,426 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $19,947 |
| VraylarCariprazine Hcl | 14 | $19,420 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $18,107 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $16,379 |
| TradjentaLinagliptin | 12 | $16,283 |
| LinzessLinaclotide | 25 | $16,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta | $411 | $177,500150 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $404 | $145,91198 claims |
| Novo NordiskOzempic | $609 | $90,49779 claims |
| MerckJanumet Xr, Janumet, Januvia | $31 | $38,21736 claims |
| AbbVieVraylar, Linzess | $559 | $35,65639 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $383 | $30,55542 claims |
| AmgenProlia | $140 | $30,26518 claims |
| PfizerEliquis | $229 | $27,86416 claims |
| Johnson & JohnsonXarelto | $16 | $13,92714 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $12,95416 claims |
| AstraZenecaFarxiga | $667 | $11,76314 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $9,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tempe
- Robert BloombergTempe$12K
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Kelly KrohnPhoenix$262K
- Jacque SokolovScottsdale$235K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Christine HarterGlendale$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.